原发性胆汁性胆管炎:探索个体化诊疗的最优选择

查看全文 作　　者：[1]尚玉龙;Patrick [2]S.C.Leung;M.Eric [2]Gershwin;[1]韩英

机构地区：[1]National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases,Xijing Hospital,Air Force Military Medical University,Xi’an 710032,China;[2]Division of Rheumatology,Allergy and Clinical Immunology,University of California,Davis 95616,USA

出　　处：《Science Bulletin》索引2022年第67卷第24期,共4页

基　　金：supported by the National Natural Science Foundation of China(81820108005 and 81900502);the National Key Research and Development Program of China(2017YFA0105704);Key Research and Development Program of Shaanxi(2021ZDLSF02-07)。 摘　　要：Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease that is characterized by inflammation of the interlobular bile ducts. Although PBC is a slowly progressive disease, with a natural history of 10–15 years leading to end-stage liver disease, highrisk cases may rapidly progress to decompensated cirrhosis or even death. As the most common autoimmune liver disease, the prevalence of PBC has been increasing globally, largely due to increased disease awareness, improved diagnosis, and treatment with ursodeoxycholic acid (UDCA). PBC is more likely to occur in middle-aged women, with a female-to-male ratio ranging from 1.6 to10;however, men have a higher disease severity [1,2]. 关键词：DIAGNOSIS INFLAMMATION PRIMARY

相关文献

参考文献（15）
引证文献（4）
耦合文献（0）

参考文献(15)

引证文献(4)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

原发性胆汁性胆管炎:探索个体化诊疗的最优选择

参考文献(15)

引证文献(4)

用户提示